Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurocrine Biosciences (NBIX) -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (1151)	7/13/2003 3:32:32 PM
From: Icebrg	Read Replies (1) \| Respond to of 1834

Body weight regulation by selective MC4 receptor agonists and antagonists. Foster AC, Joppa M, Markison S, Gogas KR, Fleck BA, Murphy BJ, Wolff M, Cismowski MJ, Ling N, Goodfellow VS, Chen C, Saunders J, Conlon PJ. Neurocrine Biosciences Inc, San Diego, California 92121, USA. afoster@neurocrine.com There has been great interest in melanocortin (MC) receptors as targets for the design of novel therapeutics to treat disorders of body weight, such as obesity and cachexia. Both genetic and pharmacological evidence points toward central MC4 receptors as the principal target. Using highly selective peptide tools for the MC4 receptor, which have become available recently, we have provided pharmacological confirmation that central MC4 receptors are the prime mediators of the anorexic and orexigenic effects reported for melanocortin agonists and antagonists, respectively. The current progress with receptor-selective small molecule agonist and antagonist drugs should enable the therapeutic potential of MC4 receptor activation and inhibition to be assessed in the clinic in the near future. ncbi.nlm.nih.gov